NASDAQ:LIPO Lipella Pharmaceuticals Q4 2024 Earnings Results & Report $0.0006 0.00 (0.00%) As of 11/12/2026 Lipella Pharmaceuticals beat analyst earnings expectations in its Q4 2024 results, released March 27, 2025. The company reported EPS of -$1.19 versus the -$2.43 consensus estimate, while revenue was $170 thousand. Research:Profile Earnings Announcement Details QuarterQ4 2024Report DateMarch 27, 2025TimeBefore Market OpensConference Call7:00 PM ET Lipella Pharmaceuticals EPS ResultsActual EPS-$1.19Consensus EPS -$2.43Beat/MissBeat by +$1.24One Year Ago EPSN/ALipella Pharmaceuticals Revenue ResultsActual Revenue$170 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsLipella Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesAnnual Report (10-K)Company ProfilePowered by Earnings DocumentsAnnual report(10-K) Lipella Pharmaceuticals Q4 2024 Earnings FAQ Did Lipella Pharmaceuticals beat earnings estimates for Q4 2024? Lipella Pharmaceuticals (NASDAQ:LIPO) reported earnings of -$1.19 per share for Q4 2024, beating the consensus estimate of -$2.43. The report was announced on Thursday, March 27, 2025. What was Lipella Pharmaceuticals' revenue for Q4 2024? Lipella Pharmaceuticals reported revenue of $170 thousand for Q4 2024. When is Lipella Pharmaceuticals' next earnings date? Lipella Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lipella Pharmaceuticals on the company's earnings history page. Lipella Pharmaceuticals Earnings HeadlinesLipella Pharmaceuticals Begins Chapter 11 Bankruptcy Restructuring ProcessMarch 31, 2026 | tipranks.comLipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11March 30, 2026 | globenewswire.comGOP wipeout … but here's WORSE news for the marketA 3 trillion dollar crisis may be building beneath the surface of the stock market, retirement accounts, pensions, and even banks. Reuters reports alarm bells echoing 2007 subprime warnings, and bestselling author Dr. Martin Weiss says this one may already be underway. His free briefing outlines five steps investors are considering to help protect their portfolios.November 13 at 1:00 AM | Weiss Ratings (Ad)Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen PlanusSeptember 18, 2025 | finance.yahoo.comLipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen PlanusSeptember 15, 2025 | prnewswire.comLIPO - Lipella Pharmaceuticals Inc Ordinary Shares Dividends | MorningstarJuly 18, 2025 | morningstar.comMSee More Lipella Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lipella Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lipella Pharmaceuticals and other key companies, straight to your email. Email Address About Lipella PharmaceuticalsLipella Pharmaceuticals (NASDAQ:LIPO) is a clinical-stage biotechnology company focused on developing localized treatments for diseases with significant unmet medical needs. The company’s research centers on liposomal drug-delivery technologies designed to deliver therapeutic agents directly to affected tissues while potentially limiting systemic exposure. Lipella’s lead candidate, LP-10, is an intravesical liposomal formulation of tacrolimus being developed for hemorrhagic cystitis, a painful bladder condition that can occur following cancer treatment. The company has also advanced LP-310, an oral liposomal formulation intended for the treatment of inflammatory and mucosal diseases of the mouth, including oral mucositis. Based in Pittsburgh, Pennsylvania, Lipella conducts its development activities primarily in the United States and focuses on advancing therapies through clinical and regulatory evaluation. The company’s programs are aimed at conditions affecting the bladder and oral cavity, where localized delivery may offer advantages over conventional systemic treatments.View Lipella Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense OpportunityThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and Growth Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
